Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Beijing Jingke Tailai Technology is a China-based biotechnology company dedicated to the research and development of innovative small molecule drugs. The company leverages its proprietary Targeted Protein Degradation (TPD) platform, specifically focusing on PROTAC technology, to address challenging therapeutic targets in oncology. Its lead research efforts are centered on developing degraders for the androgen receptor to treat advanced prostate cancer. Headquartered in Beijing, the firm integrates medicinal chemistry and structural biology to optimize its drug discovery process. Jingke Tailai is currently in the preclinical stage, working to transition its lead candidates into clinical trials.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Beijing Jingke Tailai Technology.